View Older Stories View More Recent Stories
-
Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board
-
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Ready Responders to Provide At-Home Care for Patients and Alleviate Strain on Hospitals During COVID-19 Crisis
-
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
-
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
-
Bridge Medicines Enters Exclusive License Agreement with The Rockefeller University for Novel Epigenetic Leukemia Program
-
DFP Healthcare Acquisitions Corp. Announces Closing of $230 Million Initial Public Offering
-
Sientra Reports Fourth Quarter and Full Year 2019 Financial Results
-
Sientra (SIEN) Announces $60 Million Convertible Notes Investment from Deerfield Management
-
Sientra Announces $60 Million Convertible Notes Investment from Deerfield Management
-
DFP Healthcare Acquisitions Corp. (DFPH) Prices 20M Unit IPO at $10/Unit
-
DFP Healthcare Acquisitions Corp. Announces Pricing of $200 Million Initial Public Offering
-
New Energy Risk, SHINE Medical Technologies Partner on Innovative Insurance Solution That Supports Financing of One-of-a-Kind Nuclear Medicine Facility
-
RubiconMD Secures $18M in Series C Financing Led by Deerfield to Fuel Growth in Primary Care
-
Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States
-
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
-
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
-
Element Science Raises $145.6 million Series C Financing to Advance Next-Generation Digital Wearable Platform
-
Nuvo Pharmaceuticals® Announces 2019 and Fourth Quarter Results
-
Endologix (ELGX) Announces Debt Restructuring Addressing 2020 Maturities
-
Endologix Announces Debt Restructuring Addressing 2020 Maturities
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
-
Form 4 Black Diamond Therapeuti For: Feb 03 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Quartet Health Announces New Effort to Improve Access to Mental Health Care and Patient Health Outcomes
-
Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer
-
Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer
-
The Center for Breakthrough Medicines is Building the World's Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) to Launch in King of Prussia, PA
-
/C O R R E C T I O N -- The Discovery Labs/
-
SHINE year-end report highlights construction progress, strong investor confidence
-
Vesta Healthcare Announces $30 Million Series A Led by Oak HC/FT and Deerfield to Engage and Support Caregivers
-
Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference
-
R&D Alliance Between Harvard and Deerfield Announces First Project Agreement
-
Nuvo Pharmaceuticals™ Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty
-
Yeda, the Commercial Arm of the Weizmann Institute of Science, and Deerfield Create Orchard Innovations, LLC
-
Duke University and Deerfield Management Announce Four Points Innovation
-
Conventus Orthopaedics Acquires Novel Intramedullary Technology from IntraFuse
-
Zafgen (ZFGN) and Chondrial Therapeutics Report Merger Agreement
-
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
-
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
-
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development
-
Black Diamond Therapeutics Closes $85 Million Series C Financing
-
Civetta Therapeutics Announces $53 million Series A to Advance Lead Programs and Develop Proprietary Platform Targeting Propeller Proteins
-
Quartet and Cambia Health Solutions Regional Health Plans Team up to Bring Improved Access to Mental Health Care Across the Pacific Northwest
-
Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program
-
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2019 Financial Results

